Special Issue

Viral Vector-Based Vaccines

Message from the Guest Editors

Viral vector-based vaccines have made significant progress in recent times. They utilize a modified virus as a "vector" to deliver genetic instructions for specific proteins to human cells; the body's cells then use these instructions to produce the antigen, triggering an immune response. This approach mimics a natural infection, delivering a robust and long-lasting immune memory. They are engineered to be replication-competent or replication-deficient, triggering both local and systemic immunity. The development and deployment of viral vector-based vaccines against infectious diseases, like those used in the COVID-19 pandemic or Ebola virus outbreaks, demonstrate the feasibility and effectiveness of this approach. Different viruses with different properties have been employed. They are continuously being engineered for improved safety, efficacy, and target specificity, allowing for the delivery of antigens to specific cells or tissues. Viral vector-based vaccines are in clinical trials for various diseases, showcasing their potential for broader applications. Research continues to explore the use of viral vectors for vaccines against infectious diseases and cancer.

Guest Editors

Dr. Marija Zaric

Dr. Hilary Whitworth

Dr. Arianna Marini

Deadline for manuscript submissions

31 December 2025

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/si/239682

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/vaccines

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp
Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

MDPI